C5a, a therapeutic target in sepsis

Area of Science:

• Immunology
• Inflammation Research
• Sepsis Pathophysiology

Background:

• C5a is a potent inflammatory peptide implicated in sepsis.
• Elevated plasma C5a and C5a receptor (C5aR) are observed in sepsis patients and animal models.
• Sepsis leads to systemic inflammation, organ dysfunction, and immune system defects.

Purpose of the Study:

• To investigate the therapeutic potential of C5a blockade in sepsis.
• To evaluate the effects of C5a inhibition on survival, inflammation, organ function, and immune responses in sepsis models.
• To summarize recent research and patents on anti-C5a therapy for sepsis.

Main Methods:

• Utilized cecal ligation and puncture (CLP) models in mice and rats to induce sepsis.
• Administered C5a blockade using anti-C5a antibody, anti-C5aR antibody, or a C5aR antagonist (C5aRa).
• Assessed survival rates, plasma cytokine levels (IL-6), bacterial counts, coagulation/fibrinolytic function, liver and kidney function, thymus atrophy, thymocyte apoptosis, and neutrophil functions.

Main Results:

• C5a blockade significantly improved survival in CLP animals.
• Treatment attenuated systemic inflammatory response syndrome (SIRS) by reducing IL-6 and bacterial loads.
• Preserved liver and kidney function, mitigated coagulation defects, and reduced thymus atrophy and apoptosis.
• Restored defective neutrophil functions, including chemotaxis, phagocytosis, and respiratory burst.

Conclusions:

• C5a plays a detrimental role in CLP-induced sepsis.
• C5a blockade emerges as a promising therapeutic strategy for sepsis treatment.
• Targeting C5a offers potential benefits in managing sepsis-induced inflammation, organ damage, and immune dysfunction.